Sei Investments Co. Buys Shares of 357,888 SOPHiA GENETICS SA $SOPH

Key Points

• Sei Investments Co. purchased 357,888 SOPHiA GENETICS shares worth approximately $1.77 million, giving it a 0.52% stake. Hedge funds and institutional investors collectively own 31.59% of the company.
• Analyst sentiment is mixed: BTIG Research and HC Wainwright maintain Buy ratings with price targets of $9 and $14, while the overall consensus rating is Hold with an average target of $10.
• SOPHiA GENETICS remains unprofitable after reporting a quarterly loss of $0.26 per share, worse than estimates, despite stronger-than-expected revenue. Insiders have also sold 276,092 shares over the past 90 days, though some transactions were made under pre-arranged trading plans.

Sei Investments Co. purchased a new position in shares of SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 357,888 shares of the company's stock, valued at approximately $1,772,000. Sei Investments Co. owned about 0.52% of SOPHiA GENETICS at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. First Dallas Securities Inc. purchased a new position in shares of SOPHiA GENETICS during the first quarter valued at approximately $50,000. Squarepoint Ops LLC purchased a new stake in SOPHiA GENETICS in the 3rd quarter worth approximately $49,000. Perkins Capital Management Inc. purchased a new stake in SOPHiA GENETICS in the 4th quarter worth approximately $49,000. Quadrature Capital Ltd purchased a new stake in SOPHiA GENETICS in the 4th quarter worth approximately $54,000. Finally, XTX Topco Ltd acquired a new position in SOPHiA GENETICS in the 4th quarter valued at $55,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SOPH has been the topic of a number of recent analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. BTIG Research lifted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. HC Wainwright upped their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $10.00.

Insider Buying and Selling

In other news, CTO Abhimanyu Verma sold 5,000 shares of the company's stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $6.95, for a total value of $34,750.00. Following the completion of the sale, the chief technology officer owned 187,171 shares of the company's stock, valued at $1,300,838.45. This represents a 2.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 17,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $7.29, for a total value of $123,930.00. Following the completion of the sale, the insider owned 590,887 shares of the company's stock, valued at approximately $4,307,566.23. This trade represents a 2.80% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 276,092 shares of company stock valued at $1,637,350 in the last 90 days. 4.88% of the stock is currently owned by company insiders.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: BTIG Research raised its price target for SOPH from $8 to $9 while maintaining a Buy rating. The move adds to recent analyst support and reinforces the stock’s upward momentum. BTIG Research raises SOPHiA GENETICS price target
• Positive Sentiment: SOPHiA GENETICS reached a new 12-month high following the analyst upgrade, indicating strong investor demand and a favorable near-term trading reaction. SOPHiA GENETICS reaches a new 12-month high
• Positive Sentiment: HC Wainwright continues to rate SOPH Buy with a $14 price target, well above recent trading levels. Its longer-term forecast still calls for a return to profitability, including positive EPS estimates for 2029 and 2030.
• Neutral Sentiment: Chief Technology Officer Abhimanyu Verma sold 5,000 shares for approximately $34,750 under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance and reduced his ownership by only 2.6%, it carries limited signaling value.
• Negative Sentiment: HC Wainwright lowered EPS estimates across several periods: Q3 2026 to $(0.13), FY2026 to $(0.77) from $(0.58), FY2027 to $(0.31) from $(0.20), and FY2028 to $(0.02) from positive $0.04. Estimates for Q1–Q4 2027 were also reduced, suggesting profitability may arrive later than previously expected.
• Negative Sentiment: The company’s latest quarterly loss of $(0.26) per share exceeded the expected $(0.21) loss, highlighting ongoing profitability pressure despite revenue exceeding expectations. SOPH remains deeply unprofitable, which could limit further gains if growth or the path to breakeven weakens.

SOPHiA GENETICS Price Performance

SOPH opened at $7.71 on Monday. SOPHiA GENETICS SA has a 52-week low of $2.96 and a 52-week high of $7.86. The company has a 50 day moving average of $5.63 and a two-hundred day moving average of $5.15. The company has a market cap of $646.79 million, a P/E ratio of -6.70 and a beta of 0.96. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million during the quarter, compared to analysts' expectations of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. On average, analysts expect that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

Want to see what other hedge funds are holding SOPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source